Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial

Neoadjuvant pembrolizumab (anti-PD-1) monotherapy in stage I-III dMMR colon cancer

The RESET-C trial evaluates neoadjuvant pembrolizumab monotherapy (single cycle) in stage I-III MMR-deficient (dMMR) colon cancer. These results fit within the rapid development of neoadjuvant immunotherapy for dMMR colorectal cancers, directly relevant for Lynch syndrome carriers. The study explores the efficacy and safety of this short pre-surgical approach with response evaluation before resection. This type of trial has direct implications for managing Lynch syndrome carriers with diagnosed colorectal cancer.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The efficacy of neoadjuvant immunotherapy in dMMR colorectal cancer is now well established, and this trial clarifies optimal modalities (duration, response evaluation). For oncogeneticists, prior identification of MMR/Lynch status remains an essential prerequisite that guides toward these aggressively effective neoadjuvant strategies.